ClinicalTrials.gg
RecruitingNCT07167030Updated Oct 16, 2026

Virtual Reality-Enabled Digital Storytelling

An interventional study of Virtual Reality Digital Storytelling in Primiparous Pregnant Women, sponsored by Bozok University. Recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Bozok University · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Oct 16, 2026Now RecruitingFirst site in Turkey (Türkiye)+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
112
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

Current scientific literature on VR details primarily focuses on fear and anxiety during childbirth. Variables such as attachment, fear, and self-efficacy are often considered independently. Therefore, in addition to interventions focused on the prenatal period, a need arose for holistic audiovisual and technologically supported intervention models that simultaneously address multidimensional aspects of life, such as prenatal attachment, fear of childbirth, and perception of childbirth self-efficacy.

Read the detailed description

This study is a randomized controlled trial conducted to evaluate the effects of digital storytelling applied to primiparous pregnant women via virtual reality glasses on prenatal attachment, fear of childbirth, perception of childbirth self-efficacy, and non-stress test results. The study will consist of two groups: an experimental and a control group. Participants in the experimental group will access a digital storytelling training program via virtual reality glasses and receive information and guidance on topics such as prenatal attachment, fear of childbirth, and perception of childbirth self-efficacy. Participants in the control group will receive standard care.

02

Conditions studied

  • Primiparous Pregnant Women

Keywords

  • Prenatal attachment
  • Fear of Childbirth
  • Birth Self-Efficacy
  • Virtual Reality
  • Digital Storytelling
03

In context

Lead sponsor

Bozok University is the lead sponsor of 54 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Primiparous women in their 28th week of pregnancy
  • Between the ages of 18 and 40
  • Experiencing a singleton pregnancy
  • Applied to the Yozgat City Hospital Gynecology and Obstetrics Clinic and agreed to participate in the study
  • Have a primary school education and can understand Turkish
  • Have no serious vision or balance problems that would prevent the use of VR glasses
  • Have not experienced any risky pregnancy problems (premature membrane rupture, preeclampsia, gestational diabetes, etc.)
  • Have no identified fetal anomalies
  • Have no psychiatric diagnosis

Exclusion criteria

Exclusion Criteria:

  • Pregnant women who cannot obtain a work permit and who do not agree to participate in the study will not be included in the study.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
112 participants (estimated)

Study arms

  • Experimental
    İntervention Arm

    Participants in the intervention group will receive digital storytelling modules using virtual reality (VR) headsets once a week for four weeks, starting at 28 weeks of gestation. Each module will include three topics (2-10 minutes). After each topic, there will be a rest period followed by an interactive session. The final two modules will be administered during the NST recording, and mother and baby status will be monitored. Each module, including the interactive session, will last 45-50 minutes. Participants will receive an educational brochure after the module and will be reminded via WhatsApp. Posttests (at the end of 36 weeks of gestation): * Prenatal Attachment Inventory * Wijma Birth Expectations/Experiences Questionnaire Version A * Short Version of the Labor Self-Efficacy Scale * Satisfaction Level Information Form for the VR Headset Application * NST Follow-up Form * Video Immersion Scale

    Behavioral: Virtual Reality Digital Storytelling

  • No intervention
    Control Arm

    Participants in the control group will receive routine care. Posttests (at the end of 36 weeks of gestation): * Prenatal Attachment Inventory * Wijma Birth Expectations/Experiences Questionnaire Version A * Short Version of the Labor Self-Efficacy Scale * NST Follow-up Form

Interventions

  • BehavioralVirtual Reality Digital Storytelling

    Participants in the intervention group will receive digital storytelling modules using virtual reality (VR) headsets once a week for four weeks, starting at 28 weeks of gestation. Each module will include three topics (2-10 minutes). After each topic, there will be a rest period followed by an interactive session. The final two modules will be administered during the NST recording, and mother and baby status will be monitored. Each module, including the interactive session, will last 45-50 minutes. Participants will receive an educational brochure after the module and will be reminded via WhatsApp.

06

What researchers measure

Primary outcomes

  1. Prenatal Attachment Inventory

    The Prenatal Attachment Inventory (PAI) developed by Muller (1993) is used to assess the thoughts, feelings, and states experienced by women during pregnancy and to determine their attachment to their babies during the prenatal period (Muller, 1993). The Turkish validity and reliability study of the inventory, conducted by Yılmaz and Beji (2013), consists of 21 items. Each item is a four-point Likert-type scale, ranging from 1 to 4. A minimum score of 21 and a maximum score of 84 can be obtained from the scale. Increasing scores indicate increased attachment. The scale's validity and reliability performance was found to be 0.84, with a Cronbach's alpha of 0.10.

    Time frame: Time Frame: Pre-test (before intervention) Time Frame: Post-test (after intervention: 36th week of pregnancy, after the fourth module)

  2. Wijma Childbirth Expectation/Experience Questionnaire Version A (W-DEQ-A)

    Developed by Wijma et al. (1998) to assess the level of fear of childbirth experienced by pregnant women, the scale was adapted into Turkish by Körükcü (2009). Version A of the W-DEQ is a 33-item scale. Responses are numbered from 0 to 5 and are on a six-point Likert-type scale. The minimum score is 0, and the maximum score is 165. A high total score indicates a high level of fear. In the validity and reliability study of the scale, Cronbach's Alpha was found to be 0.89 (Körükcü, 2009).

    Time frame: Time Frame: Pre-test (before intervention) Time Frame: Post-test (after intervention: 36th week of pregnancy, after the fourth module)

  3. Short Version of the Labor Self-Efficacy Scale

    The Turkish adaptation of the scale, developed to measure women's self-efficacy for childbirth, was conducted by Ersoy (2011). The scale consists of two sub-dimensions: competence and outcome expectation, and a total of 32 questions. Scores for each sub-dimension range from 16 to 160. As the score on each sub-dimension increases, the competence and outcome expectation for childbirth increases. The Likert-type scale is scored from 1 to 10. In the outcome expectation sub-dimension of the scale, 1 represents "not at all useful," and 10 represents "very useful." In the competence expectation sub-dimension, questions 1 to 13 are scored as 1 "completely confident," 10 represents "not at all confident," and the remaining questions are scored as 1 "not at all confident," and 10 represents "completely confident." The first 13 questions in the competence expectation sub-dimension of the scale are reverse-scored. The total score obtained from the scale ranges from 32 to 320. As the score on the

    Time frame: Time Frame: Pre-test (before intervention) Time Frame: Post-test (after intervention: 36th week of pregnancy, after the fourth module)

Secondary outcomes

  1. NST Follow-up Form

    This form consists of sections containing the emotional state and NST findings experienced by pregnant women during the NST procedure. The NST results in the NST Follow-up Form will be evaluated and recorded by the researcher.

    Time frame: Time Frame: 34th weeks of pregnancy (during the last two modules) Time Frame: 36th weeks of pregnancy (during the last two modules)

Other outcomes

  1. Video Immersion Scale (VIS)

    The Video Immersion Scale, developed by Visser et al. (2016), was adapted into Turkish by Deryakulu et al. (2019). The scale consists of five factors and a total of 15 items. The Cronbach's alpha internal consistency coefficients calculated for the subfactors and the entirety of the Video Immersion Scale, which is a seven-point Likert-type scale, are as follows: Factor 1 (Attention) 0.57; Factor 2 (Narrative World Immersion) 0.73; Factor 3 (Identity) 0.87; Factor 4 (Empathy) 0.78; Factor 5 (Emotion) 0.69; and for the entire scale, 0.90. In this study, the Cronbach's alpha reliability coefficients for the factors were, respectively, Factor 1 (Attention) 0.57; Factor 2 (Entering the narrative world) was calculated as 0.71; Factor 3 (Identity) as 0.70; Factor 4 (Empathy) as 0.72; Factor 5 (Emotion) as 0.78; and 0.81 for the entire scale.

    Time frame: Time Frame: Post-intervention (post-intervention: 36th week of pregnancy, after the fourth module)

  2. Virtual Reality Glasses Application Satisfaction Level Information Form

    This form will include questions prepared by researchers to determine satisfaction with the video watched with virtual reality glasses.

    Time frame: Time Frame: Post-intervention (post-intervention: 36th week of pregnancy, after the fourth module)

07

Study locations

1 of 1 sites recruiting
  • Yozgat Şehir Hastanesi
    Yozgat, Yozgat 66100, Turkey (Türkiye)
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared to protect participant confidentiality and as data was collected only for this study.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jul 2026 (actual). Primary completion is estimated for Nov 2026, 4 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Nov 2025 → Jul 2026, on Oct 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2025
First posted
Sep 11, 2025
StartActual
Jul 1, 2026was Nov 2025
Primary completionEst.
Nov 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 16, 2026
Sites
1 site added — first site in Turkey (Türkiye)
Show site
  • Yozgat Şehir Hastanesi · Yozgat, Turkey (Türkiye)
Oct 16, 2026
Start date
Nov 1, 2025→Jul 1, 2026 (actual)
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Turkey (Türkiye)
    Show site
    • Yozgat Şehir Hastanesi · Yozgat, Turkey (Türkiye)
    Start date Nov 1, 2025→Jul 1, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07167030
Lead sponsor
Bozok University
Responsible party
RUKİYE DİKMEN (Lecturer, Bozok University) — Principal investigator
First posted
Sep 11, 2025
Start date
Jul 1, 2026
Primary completion
Nov 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Oct 16, 2026

Study contacts

RUKİYE DİKMEN, PhD Student
Contact
rukiye.dikmen@yobu.edu.tr
+905433686510

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion